Company news

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news

Catalyst Pharmaceuticals, Inc. news releases on 6ix. Latest, Jan 23, 2023: Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing…

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news

Press releases — page 3

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid

Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst

Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing

Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences

Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan

Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021

Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS

Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations

Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®

Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer

Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors

Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®

Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021

Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program

Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021

Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021

Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update

Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update